Professionals cross a bridge towards a regulatory consultation pavilion, with a PMDA logo sign and Japanese flag.
Japan’s regulatory system is changing, and your company’s strategy may need to change with it. From Japanese clinical-data requirements and biosimilar development to orphan designation, English submissions and pricing incentives, we examine what recent PMDA and MHLW reforms mean for your team’s development plans, investment decisions and partnerships in Japan.